TY - JOUR
T1 - Ablation strategies for different types of atrial fibrillation in Europe: Results of the ESC-EORP EHRA Atrial Fibrillation Ablation Long-Term registry
AU - Schmidt, Boris
AU - Brugada, Josep
AU - Arbelo, Elena
AU - Laroche, Cécile
AU - Bayramova, Sevda
AU - Bertini, Matteo
AU - Letsas, Konstantinos P.
AU - Pison, Laurent
AU - Romanov, Alexander
AU - Scherr, Daniel
AU - Tilz, Roland Richard
AU - Maggioni, Aldo
AU - Adragao, Pedro
AU - Lund, Juha
AU - Haman, Ludek
AU - Oliveira, Marino Martins
AU - Dagres, Nikolaos
N1 - Funding Information:
Conflict of interest: R.R.T., speakers bureau: Biosense Webster, Medtronic, Abbott. N.D., research grants from Abbott, Biotronik, Boston Scientific and Medtronic to the institution without personal benefits. All other authors declared no conflict of interest.
Publisher Copyright:
© 2019 Published on behalf of the European Society of Cardiology. All rights reserved.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/4/1
Y1 - 2020/4/1
N2 - Aims: The ESC EORP EHRA Atrial Fibrillation (AF) Ablation Long-Term registry was designed to assess management and outcomes of AF catheter ablation procedures in Europe. To investigate the current ablation approaches and their outcomes for patients with paroxymal AF (PAF) and non-PAF in Europe. Methods and results: Data from index ablations were collected in 27 European countries at 104 centres in a prospective fashion. Pre-procedural, procedural, and 1-year follow-up data were captured on a web-based electronic case record form. Data on the ablation procedure were available for 3446 patients. Of these, 2513 patients and 933 patients underwent pulmonary vein isolation (PVI) or PVI plus (PVIplus) additional ablation, respectively. The ablation strategy was limited to PVI in 81% and 56% of patients in the PAF and non-PAF group, respectively (P < 0.001). In the non-PAF group, left atrial linear ablation and ablation of complex fragmented atrial electrograms were more commonly performed. Arrhythmias recurrence after PVI was 29% and 39% in the PAF and non-PAF group, respectively (P < 0.001) and 42% after PVIplus in both groups. Atrial fibrillation related hospital admissions were more common in the PVIplus group (20% vs. 14%). A very low procedural complication rate was observed. No relevant differences were observed with regard to repeat ablation (PVI 9% and PVIplus 11%). Conclusion: In patients with PAF and non-PAF, the ablation strategies of PVI and PVIplus led to similar arrhythmia-free survival rates after 1 year. A considerable hospital readmission rate was noted.
AB - Aims: The ESC EORP EHRA Atrial Fibrillation (AF) Ablation Long-Term registry was designed to assess management and outcomes of AF catheter ablation procedures in Europe. To investigate the current ablation approaches and their outcomes for patients with paroxymal AF (PAF) and non-PAF in Europe. Methods and results: Data from index ablations were collected in 27 European countries at 104 centres in a prospective fashion. Pre-procedural, procedural, and 1-year follow-up data were captured on a web-based electronic case record form. Data on the ablation procedure were available for 3446 patients. Of these, 2513 patients and 933 patients underwent pulmonary vein isolation (PVI) or PVI plus (PVIplus) additional ablation, respectively. The ablation strategy was limited to PVI in 81% and 56% of patients in the PAF and non-PAF group, respectively (P < 0.001). In the non-PAF group, left atrial linear ablation and ablation of complex fragmented atrial electrograms were more commonly performed. Arrhythmias recurrence after PVI was 29% and 39% in the PAF and non-PAF group, respectively (P < 0.001) and 42% after PVIplus in both groups. Atrial fibrillation related hospital admissions were more common in the PVIplus group (20% vs. 14%). A very low procedural complication rate was observed. No relevant differences were observed with regard to repeat ablation (PVI 9% and PVIplus 11%). Conclusion: In patients with PAF and non-PAF, the ablation strategies of PVI and PVIplus led to similar arrhythmia-free survival rates after 1 year. A considerable hospital readmission rate was noted.
UR - http://www.scopus.com/inward/record.url?scp=85083041381&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/14af72e3-bbf2-3f4e-a3b2-d03e7fa3eb04/
U2 - 10.1093/europace/euz318
DO - 10.1093/europace/euz318
M3 - Journal articles
C2 - 31821488
AN - SCOPUS:85083041381
SN - 1099-5129
VL - 22
SP - 558
EP - 566
JO - Europace
JF - Europace
IS - 4
ER -